Related Experiment Video
Updated: Jan 10, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Tumor-derived extracellular vesicles: Bridging communication and next-generation theranostics
Jace Chen1, Apple Verdiell1, Carlos Formoso2
1Pritzker School of Molecular Engineering, The University of Chicago, Chicago, IL 60637, USA; Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA.
Abstract:
Cancer remains one of the leading causes of mortality worldwide, and despite advancements in therapeutic strategies-including chemotherapy, radiotherapy, immunotherapy, surgery, hormone therapy, and targeted therapy-a definitive cure remains elusive. In recent years, tumor-derived extracellular vesicles (TD-EVs) have garnered attention due to their critical roles in tumorigenesis, angiogenesis, and metastasis. Generated via biogenesis pathways involving the endosomal sorting complex required for transport (ESCRT), TD-EVs facilitate diverse mechanisms that promote tumor growth and survival. These include the induction of epithelial-mesenchymal transition (EMT), stimulation of angiogenesis, suppression of natural killer (NK) and T cell activity, promotion of M2 macrophage polarization, and facilitation of metastasis. Beyond their tumor-promoting functions, TD-EVs also hold promise as diagnostic and therapeutic tools. For example, EV PD-L1 has emerged as a biomarker for the liquid biopsy, reflecting tumor immune evasion, while engineered TD-EVs loaded with therapeutic cargos such as siRNAs or chemotherapeutic agents have shown potential in targeted tumor delivery. Their presence in bodily fluids and selective enrichment of tumor-specific cargo position them as valuable candidates for liquid biopsy applications, enabling non-invasive monitoring of disease progression and treatment responses. Furthermore, engineered TD-EVs are being explored as delivery systems for chemotherapeutics, RNA interference molecules, and gene-editing tools. Despite these advances, different challenges hinder the clinical translation of TD-EV-based applications. These include the heterogeneity of EV populations, lack of standardized isolation and characterization protocols, and difficulty in distinguishing TD-EVs from normal EVs in complex biological samples. Key obstacles also include the pronounced heterogeneity of EV populations and the lack of standardized isolation and characterization protocols. This review explores the multifaceted roles of TD-EVs in cancer biology and their potential utility in diagnosis, prognosis, and therapeutic intervention.
Insights
Tumor-derived extracellular vesicles (TD-EVs) play key roles in cancer progression and metastasis. These vesicles show promise for cancer diagnosis and targeted therapy, but challenges remain for clinical use.
Area of Science:
- Oncology
- Cell Biology
- Biotechnology
Background:
- Cancer remains a leading global cause of death despite various treatments.
- Tumor-derived extracellular vesicles (TD-EVs) are increasingly recognized for their roles in cancer development.
- TD-EVs influence tumorigenesis, angiogenesis, metastasis, and immune evasion.
Purpose of the Study:
- To review the multifaceted roles of TD-EVs in cancer biology.
- To explore the diagnostic and therapeutic potential of TD-EVs.
- To identify challenges hindering the clinical translation of TD-EV applications.
Main Methods:
- Literature review of TD-EVs in cancer.
- Analysis of TD-EVs' mechanisms in tumor growth and spread.
- Evaluation of TD-EVs as biomarkers and therapeutic delivery systems.
Main Results:
- TD-EVs promote cancer via EMT, angiogenesis, immune suppression, and metastasis.
- EV PD-L1 is a potential liquid biopsy biomarker for immune evasion.
- Engineered TD-EVs show promise for targeted drug and nucleic acid delivery.
Conclusions:
- TD-EVs are crucial in cancer progression and offer potential for liquid biopsy and targeted therapies.
- Standardization of isolation, characterization, and distinguishing TD-EVs from normal EVs are critical challenges.
- Further research is needed to overcome obstacles for clinical translation of TD-EV-based strategies.
More Related Videos
08:50Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...